Stocks · US
NBIX
XNAS
Neurocrine Biosciences Inc
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E20.78x
P/B3.97x
P/S4.34x
EPS$6.94
ROE19.10%
ROA13.16%
Dividend yield0.00%
EV/EBITDA17.12x
Debt/Equity0.00
Free cash flow$870M
Returns and 52-week range
1W+5.18%
1M-6.51%
3M-18.36%
6M+11.16%
1Y+6.19%
YTD+3.49%
52W high$186.12
52W low$122.14
From 52W high-21.82%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| Charles River Laboratories International, Inc. | $14.8B | — | 5.22 | +5.71% |
| Exelixis Inc | $14.6B | 16.94 | 7.91 | -1.15% |
| Solventum Corporation | $15.0B | 10.45 | 3.12 | -5.07% |
| 트위스트 바이오사이언스 | $13.6B | — | 30.49 | +33.88% |
| 템퍼스 AI | $15.2B | — | 34.09 | +11.39% |
| Corcept Therapeutics Inc. | $13.2B | 242.09 | 18.69 | +7.12% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.